Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma Exchange for Severe Crescentic IgA Nephropathy
NCT02647255Phase 3Terminated
- Sponsor
- Peking University First Hospital
- Start
- Mar 2016
- Primary completion
- Oct 2020
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Peking University First Hospital. Primary endpoint: End-stage renal disease or death at 12 months. Started Mar 2016; status: terminated.
Beyond the preview
Go deeper on NCT02647255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02647255.